Skip to main content

AMGN

AMGEN INC
ShareXLinkedInReddit
Sector
Health Care
Industry
Biotechnology
Last price
$363.39
As of

Active signals for AMGN

  • highTRIAL_TERMINATION

    Phase 3 trial terminated early — AMGEN Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Recei

  • highTRIAL_TERMINATION

    Phase 3 trial terminated early — AMGEN First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial T

  • mediumEARNINGS_BEAT

    Q4-2025: Beat consensus by 9.6% — EPS $5.29 vs $4.8283 estimate

  • mediumEARNINGS_BEAT

    Q3-2025: Beat consensus by 10.3% — EPS $5.64 vs $5.1144 estimate

  • mediumEARNINGS_BEAT

    Q1-2026: Beat consensus by 6.1% — EPS $5.15 vs $4.8522 estimate

Top institutional holders of AMGN (13F)

FundMarket value% portfolioQoQ
CITADEL ADVISORS LLC$270.3M0.04%,
CITADEL ADVISORS LLC$250.6M0.04%-20.1%
MILLENNIUM MANAGEMENT LLC$96.4M0.04%+305.3%
MILLENNIUM MANAGEMENT LLC$78.4M0.03%,
RENAISSANCE TECHNOLOGIES LLC$47.2M0.06%,
D. E. Shaw & Co., Inc.$39.6M0.02%+12.2%
D. E. Shaw & Co., Inc.$34M0.02%-20.2%
D. E. Shaw & Co., Inc.$30.4M0.02%,
MILLENNIUM MANAGEMENT LLC$22.1M0.01%-75.7%
Point72 Asset Management, L.P.$6.5M0.01%+300.0%
Bridgewater Associates, LP$5.2M0.02%+389.2%
TWO SIGMA INVESTMENTS, LP$4.6M0.01%+1300.0%
Bridgewater Associates, LP$3.2M0.01%,
TWO SIGMA INVESTMENTS, LP$2.7M0.00%-45.7%
Point72 Asset Management, L.P.$1.5M0.00%,
Bridgewater Associates, LP$988K0.00%-73.3%
TWO SIGMA INVESTMENTS, LP$282K0.00%,

Sourced from quarterly 13F filings with the U.S. Securities and Exchange Commission.

Recent SEC filings, AMGN

Related tickers

See more AMGN signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Sign in to track AMGN in your watchlist and get notified the moment a new signal fires.

Track AMGN on Kresmion →